Eupraxia Pharmaceuticals Performance
| EPRXFDelisted Stock | USD 2.79 0.04 1.45% |
The firm shows a Beta (market volatility) of -0.78, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Eupraxia Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Eupraxia Pharmaceuticals is likely to outperform the market. Eupraxia Pharmaceuticals right now shows a risk of 0.0%. Please confirm Eupraxia Pharmaceuticals total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Eupraxia Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eupraxia Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Eupraxia Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 150.1 K | |
| Total Cashflows From Investing Activities | -14.4 M |
Eupraxia |
Eupraxia Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 279.00 in Eupraxia Pharmaceuticals on August 24, 2024 and sell it today you would earn a total of 0.00 from holding Eupraxia Pharmaceuticals or generate 0.0% return on investment over 90 days. Eupraxia Pharmaceuticals is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Eupraxia, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Eupraxia Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eupraxia Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Eupraxia Pharmaceuticals, and traders can use it to determine the average amount a Eupraxia Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EPRXF |
Based on monthly moving average Eupraxia Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eupraxia Pharmaceuticals by adding Eupraxia Pharmaceuticals to a well-diversified portfolio.
Eupraxia Pharmaceuticals Fundamentals Growth
Eupraxia Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Eupraxia Pharmaceuticals, and Eupraxia Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eupraxia Pink Sheet performance.
| Return On Equity | -0.89 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 43.78 M | |||
| Shares Outstanding | 21.39 M | |||
| Price To Book | 3.89 X | |||
| EBITDA | (21.96 M) | |||
| Cash And Equivalents | 35.46 M | |||
| Cash Per Share | 1.66 X | |||
| Total Debt | 9.26 M | |||
| Debt To Equity | 0.42 % | |||
| Book Value Per Share | 0.95 X | |||
| Cash Flow From Operations | (14.64 M) | |||
| Earnings Per Share | (0.98) X | |||
| Total Asset | 31.22 M | |||
About Eupraxia Pharmaceuticals Performance
By analyzing Eupraxia Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Eupraxia Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Eupraxia Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Eupraxia Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Eupraxia Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.Things to note about Eupraxia Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eupraxia Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Eupraxia Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eupraxia Pharmaceuticals is not yet fully synchronised with the market data | |
| Eupraxia Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eupraxia Pharmaceuticals has accumulated about 35.46 M in cash with (14.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Roughly 12.0% of the company shares are held by company insiders |
- Analyzing Eupraxia Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eupraxia Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eupraxia Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eupraxia Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eupraxia Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eupraxia Pharmaceuticals' pink sheet. These opinions can provide insight into Eupraxia Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Eupraxia Pink Sheet
If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |